

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/005625 A3

(51) International Patent Classification⁷: C12N 7/00, 5/06, C12Q 1/70, A61K 39/29, G01N 33/50

(21) International Application Number:
PCT/CA2004/001009

(22) International Filing Date: 14 July 2004 (14.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,436,104 14 July 2003 (14.07.2003) CA
2,454,540 6 February 2004 (06.02.2004) CA

(71) Applicant (for all designated States except US): MCGILL
UNIVERSITY [CA/CA]; Office of Technology Transfer,
3550 University Street, Montreal, Quebec H3A 2A7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SONENBERG,
Nahum-[CA/CA];-5609-Blossom Avenue, Côte St-Luc,
Quebec H4W 2S9 (CA). LOPEZ LASTRA, Marcelo
[CL/CL]; MLL: Toconce 1520, Las Coudes, Santiago
(CL).

(74) Agents: DUBUC, J. et al.; GOUDREAU GAGE DUBUC,
Stock Exchange Tower, 800 Place Victoria, Suite 3400, P.O
Box 242, Montreal, Quebec H4Z 1E9 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
7 April 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR INDUCING HEPATITIS C VIRUS (HCV) REPLICATION *IN VITRO*, CELLS AND CELL LINES
ENABLING ROBUST HCV REPLICATION AND KIT THEREFOR

WO 2005/005625 A3

(57) Abstract: The present invention relates to hepatitis C virus (HCV). More particularly, the invention relates to the development of a tool suitable for the search, discovery and validation of novel HCV antiviral drugs and therapies (e.g. vaccine). The invention further relates to methods for inducing HCV replication *in vitro*, and more particularly to a simple *in vitro* replication assay for HCV. In addition, the invention relates to the use of the methods of the present invention to prognose the resistance/sensitivity of a particular strain of HCV to a chosen anti-HCV agent. In one embodiment, the present invention relates to an adaptation of a therapeutic regimen for a patient infected with HCV which takes into account the resistance/sensitivity phenotype of the HCV strain which infects same. The invention more particularly, relates to a method for generating an established cell line which produces hepatitis C virus (HCV) comprising transforming peripheral blood mononuclear cells (PBMCs) which produce HCV with Epstein Barr virus (EBV). The invention also relates to an EBV established B-cell line capable of replicating complete and infectious HCV. As well, the invention relates to a cell-based *in vitro* replication system for HCV comprising an EBV-transformed B-cell capable of replicating complete and infectious HCV, and a second cell population having HCV tropism and in which robust HCV replication occurs, so that under appropriate culture conditions the second cell population can become infected by the infectious HCV produced by the EBV-transformed B-cell. The present invention also relates to kits for transforming a HCV-producing cell and to kits for diagnosing HCV in a patient.